Thymosin Alpha-1: 2026 Immune Dosing Guide

Thymosin Alpha-1 (Tα1, thymalfasin) is the most clinically validated peptide currently used for immune modulation. Marketed internationally as Zadaxin, it is approved in over 35 countries (not the U.S.) for hepatitis B, hepatitis C, and as an immune adjunct in sepsis and cancer protocols. The standard dosing protocol, 1.6 mg subcutaneous twice weekly , comes directly from the Zadaxin label and decades of clinical trial data. Unlike BPC-157 and TB-500, Tα1 was not part of the February 27, 2026 FDA reclassification because it never sat in the same Category 2 status; it has remained available through 503A compounding pharmacies under prescription throughout the 2023–2026 period. This guide covers everything newly-prescribed patients and experienced biohackers need: how Tα1 works, the standard 1.6 mg twice-weekly protocol, post-illness and long COVID applications, reconstitution math, side effects, costs, and the regulatory context.
Table of Contents
- What is Thymosin Alpha-1?
- How Tα1 Works
- 2026 Regulatory Status
- Standard 1.6 mg Twice-Weekly Protocol
- Cycle Lengths and Variants
- Reconstitution Math
- Side Effects and Management
- Drug interactions
- Lab Monitoring
- Storage & Travel
- Common Stacks and Combinations
- Cost Considerations
- Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymic extract by Allan Goldstein and colleagues in the 1970s. It is the most clinically-validated peptide covered on this site by a wide margin, owing to its development pathway as Zadaxin (thymalfasin), marketed by SciClone and approved in 35+ countries for hepatitis B, hepatitis C, and as an immune-modulating adjunct in cancer and sepsis settings.
Tα1 is most often used today for:
- Post-illness immune restoration (e.g., post-COVID, post-mononucleosis, post-Lyme)
- Long COVID protocols
- Chronic immune dysregulation (frequent infections, lymphopenia)
- Pre- and post-surgical immune support
- Cancer immunotherapy adjunct (off-label, with oncology supervision)
- Hepatitis B and hepatitis C (per Zadaxin’s approved indication outside the U.S.)
- Elderly immune-support protocols
How Tα1 Works
Thymosin Alpha-1 acts on multiple arms of the adaptive immune system:
- Dendritic-cell maturation , promoting effective antigen presentation to T cells
- T-cell activation , both CD4+ helper T cells and CD8+ cytotoxic T cells
- Th1 polarization , pushing the helper T cell response toward antiviral and antitumor patterns rather than allergic / Th2 patterns
- Reduction of T-cell apoptosis , particularly in lymphopenic states (e.g., severe COVID-19)
Mechanistically Tα1 works upstream of the immune response, modulating how the immune system organizes itself rather than directly killing pathogens. This is the rationale for using it in chronic infections, post-illness recovery, and cancer adjunct contexts where the immune system needs orchestration support.
2026 Regulatory Status
Thymosin Alpha-1’s regulatory history is distinct from the BPC-157 / TB-500 cluster. Thymalfasin was placed under a 2023 FDA action that limited compounding of certain peptides; however, Tα1 remained available via 503A compounding pharmacies under prescription throughout the 2023–2026 period.
As a result, Tα1 was not part of the February 27, 2026 reclassification announcement, it never needed to be reclassified because it had not been moved into the restricted Category 2 status in the same way as BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax. As of April 2026, Tα1 is broadly available by prescription at compounding pharmacies and through telehealth peptide clinics including Marek Health, Ways2Well, Concierge MD, Restorative Wellness, Life Force, and Maximus.
Eric Topol’s March 2026 Substack treats Thymosin Alpha-1 as the “most legitimate” peptide in this category, noting it has the strongest evidence base.
Standard 1.6 mg Twice-Weekly Protocol
The defining Tα1 protocol, and the one most-prescribed in 2026, is the 1.6 mg subcutaneous twice weekly regimen. This dose is anchored directly in the Zadaxin label (1.6 mg twice weekly for 6 months in the chronic hepatitis B indication) and reflects decades of clinical trial use.
| Parameter | Standard Protocol |
|---|---|
| Dose | 1.6 mg subcutaneous |
| Frequency | Twice weekly (e.g., Monday and Thursday) |
| Total weekly dose | 3.2 mg |
| Injection sites | Abdomen on Day 1, alternate site on Day 4 |
| Cycle length (general immune support) | 8 weeks, then reassess |
| Cycle length (chronic hepatitis B per Zadaxin label) | 6 months continuous |
This is the protocol most-prescribed by Marek Health, Ways2Well, Concierge MD, and other major telehealth peptide clinics in 2026. For most general immune-support indications, an 8-week cycle followed by a reassessment is the default; chronic viral hepatitis indications follow the longer 6-month label protocol.
Cycle Lengths and Variants
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| General immune support | 1.6 mg | 2x/week | 8 weeks on, 4 weeks off |
| Acute / post-illness recovery | 1.6 mg | 2x/week | 4–8 weeks continuous |
| Long COVID / chronic immune dysfunction | 1.6 mg | 3x/week tapering to 2x/week | 4 weeks intensive, then maintenance |
| Chronic hepatitis B (Zadaxin label) | 1.6 mg | 2x/week | 6 months continuous |
| Pre-/post-surgical support | 1.6 mg | 2x/week | 2 weeks before through 4 weeks after |
| Once-weekly variant (same total) | 3.2 mg | 1x/week | Cycled |
| Cancer immunotherapy adjunct (off-label) | 1.6 mg | 2–3x/week | Long courses with oncology supervision |
| Elderly low-frequency support | 1.6 mg | 1x/week | Indefinite |
Reconstitution Math
Tα1 is dispensed as a lyophilized powder, most commonly in 5 mg vials (10 mg also available). Reconstitute with bacteriostatic water (BAC water, sterile water with 0.9% benzyl alcohol). The 1.6 mg dose makes the math slightly less clean than with round numbers like 250 mcg or 2.5 mg.
| Vial | BAC Water Added | Concentration | For 1.6 mg, draw |
|---|---|---|---|
| 5 mg | 5 mL | 1 mg/mL | 1.6 mL |
| 5 mg | 3.125 mL | 1.6 mg/mL | 1.0 mL (full syringe) |
| 10 mg | 10 mL | 1 mg/mL | 1.6 mL |
The 5 mg + 5 mL recipe (1 mg/mL) is the most common; you draw 1.6 mL of solution per dose. Some clinicians prefer the 5 mg + 3.125 mL recipe (1.6 mg/mL) for syringe simplicity, exactly 1 mL per dose.
One 5 mg vial = 3 doses at 1.6 mg = approximately 10 days at twice-weekly dosing. Stability: Refrigerated reconstituted Tα1 is generally considered stable for 28–30 days.
Side Effects and Management
Thymosin Alpha-1 has the strongest safety profile of the peptides covered on this site, by a wide margin, owing to decades of clinical use globally as Zadaxin.
- Injection-site reactions , most common, typically mild
- Transient discomfort, fatigue, or muscle ache in first week, uncommon
- Rash, transient eosinophilia , rare
- Generally well tolerated across published trials
Theoretical concern, autoimmunity and transplant: Tα1 promotes immune activation. It should be used cautiously, or avoided, in patients with active autoimmune disease (lupus, RA on biologics, MS) or on immunosuppressants for solid organ transplant. Discuss with your prescriber if either situation applies.
Drug interactions
Drug interactions to know
Educational summary only, not medical advice. Consult your prescriber. See full interactions lookup.
Lab Monitoring
Thymosin Alpha-1 is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.
Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.
During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.
What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Below -18°C (-0.4°F) desiccated per Zadaxin label; protect from light.
Reconstituted: Reconstitute and use same day; stable 2-7 days at 4°C per label. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: Thymosin Alpha-1 is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted Thymosin Alpha-1 at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.
Common Stacks and Combinations
Tα1 is more often run as monotherapy than the other peptides on this site , its evidence base supports it standing alone. When stacked, common combinations include:
- Tα1 + TB-500 , immune + recovery, popular post-illness or post-surgical
- Tα1 + LL-37 , immune + antimicrobial, chronic infection
- Tα1 + KPV , immune dysregulation with inflammatory component
- Tα1 + BPC-157 + GHK-Cu , comprehensive recovery stack post-major-illness
Cost Considerations
Tα1 is the most expensive peptide in this category on a per-dose basis.
- 5 mg vial: $160–$280 at compounding pharmacy
- 10 mg vial: $280–$450
- Cost per 1.6 mg dose (from a $200, 5 mg vial): ~$65/dose
- Weekly cost at 1.6 mg twice weekly: ~$130/week
- Eight-week cycle cost: ~$1,040 in peptide alone, plus consumables
Frequently Asked Questions
Is Thymosin Alpha-1 the same as Zadaxin?
Yes. Zadaxin is SciClone’s brand name for synthetic thymalfasin, which is Thymosin Alpha-1. The standard 1.6 mg twice-weekly dosing protocol comes directly from the Zadaxin label.
Why was Tα1 not part of the February 2026 reclassification?
Because it didn’t need to be. Tα1’s regulatory history is distinct from BPC-157 and TB-500 , it remained available via 503A compounding pharmacies under prescription throughout the 2023–2026 period when many other peptides were restricted. The February 27, 2026 reclassification covered 14 of the 19 peptides that had been moved to Category 2; Tα1 was not in that group.
Can I use Tα1 if I have an autoimmune disease?
This requires individualized clinical judgment. Tα1 promotes immune activation, which is the mechanism of benefit in immunocompromised states but is the theoretical concern in active autoimmunity. Patients with lupus, rheumatoid arthritis on biologics, multiple sclerosis, or other active autoimmune disease should not start Tα1 without their treating specialist’s input.
How long until I notice a benefit?
Tα1 works upstream of the immune response, so subjective effects are typically slower to emerge than with peptides aimed at acute symptoms. Clinical trial endpoints in hepatitis B run 6 months. Most users in post-illness or long COVID protocols report perceptible benefit at 4–6 weeks of the 1.6 mg twice-weekly regimen.
Is Tα1 used in cancer?
Off-label, yes , there is a developing literature on Tα1 as an adjunct to chemotherapy and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer. This use should always be coordinated with the patient’s oncology team rather than initiated independently.
Can I do once-weekly instead of twice-weekly?
Some protocols use 3.2 mg once weekly , the same total weekly dose split differently. The Zadaxin label and most clinical practice use the twice-weekly cadence because Tα1’s plasma half-life is ~2 hours and biological effect persists for days but not a full week. Twice weekly is generally preferred for active immune-support indications; once weekly is used for low-intensity maintenance.
What’s the half-life of Tα1?
Plasma half-life is approximately 2 hours in healthy adults. This is the best-characterized PK profile among the peptides covered on this site, owing to Zadaxin’s regulatory approval pathway. Biological effect on T-cell and dendritic-cell function persists for days, which supports twice-weekly dosing.
Educational use only , not medical advice. Consult your prescribing physician.
- Demand a current third-party Certificate of Analysis (CoA) listing peptide identity (mass spec), purity ≥98%, and endotoxin testing.
- Verify the lyophilized vial weight matches what’s printed – under-filled vials are the most common form of dose-cheating in this market.
- Storage: Reconstituted Tα1 stable 30 days refrigerated.
- Typical research route: subcutaneous.
- Thymosin alpha-1 (Zadaxin) is approved in 30+ countries and has the strongest evidence base of any ‘thymic peptide’. Compounding-pharmacy Tα1 is widely available.
- “Research-use-only” labeling has legal weight – self-administration may violate state and federal law in your jurisdiction.
References
- Garaci E, Pica F, Rasi G, Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000;22(12):1067-1076. PubMed.
- Costantini C, Bellet MM, Pariano M, et al. A reappraisal of thymosin alpha1 in cancer therapy. Front Oncol. 2019;9:873. PubMed.
- King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-178. PubMed.
- Wu M, Ji JJ, Zhong L, et al. Thymosin alpha1 therapy in critically ill patients with sepsis: a multicenter randomized clinical trial. Intensive Care Med. 2013;39(10):1701-1709. PubMed.
- SciClone Pharmaceuticals. Zadaxin (thymalfasin) prescribing information (international markets). PubMed.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. FDA.






